257 related articles for article (PubMed ID: 38475811)
1. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
Du J; Lin Z; Fu XH; Gu XR; Lu G; Hou J
Cell Commun Signal; 2024 Mar; 22(1):177. PubMed ID: 38475811
[TBL] [Abstract][Full Text] [Related]
2. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.
Sucur A; Jajic Z; Artukovic M; Matijasevic MI; Anic B; Flegar D; Markotic A; Kelava T; Ivcevic S; Kovacic N; Katavic V; Grcevic D
Arthritis Res Ther; 2017 Jun; 19(1):142. PubMed ID: 28619088
[TBL] [Abstract][Full Text] [Related]
3. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Song N; Cui K; Zeng L; Li M; Fan Y; Shi P; Wang Z; Su W; Wang H
Eur J Pharmacol; 2024 Mar; 967():176357. PubMed ID: 38309677
[TBL] [Abstract][Full Text] [Related]
4. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
Mehrpouri M
Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
6. Role of CXC group chemokines in lung cancer development and progression.
Spaks A
J Thorac Dis; 2017 Apr; 9(Suppl 3):S164-S171. PubMed ID: 28446981
[TBL] [Abstract][Full Text] [Related]
7. Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells.
Gouwy M; Struyf S; Leutenez L; Pörtner N; Sozzani S; Van Damme J
Immunobiology; 2014 Mar; 219(3):218-29. PubMed ID: 24268109
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
9. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
Morein D; Erlichman N; Ben-Baruch A
Front Immunol; 2020; 11():952. PubMed ID: 32582148
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
11. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
12. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.
Li Y; Zheng Y; Li T; Wang Q; Qian J; Lu Y; Zhang M; Bi E; Yang M; Reu F; Yi Q; Cai Z
Oncotarget; 2015 Sep; 6(27):24218-29. PubMed ID: 26155942
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome.
Patsouras MD; Sikara MP; Grika EP; Moutsopoulos HM; Tzioufas AG; Vlachoyiannopoulos PG
J Autoimmun; 2015 Dec; 65():30-7. PubMed ID: 26283469
[TBL] [Abstract][Full Text] [Related]
14. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
15. Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis.
Coniglio SJ
Front Endocrinol (Lausanne); 2018; 9():313. PubMed ID: 29930538
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C.
Broxmeyer HE; Pelus LM; Kim CH; Hangoc G; Cooper S; Hromas R
Exp Hematol; 2006 Aug; 34(8):1069-77. PubMed ID: 16863913
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Choi HY; Yong CS; Yoo BK
Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
[TBL] [Abstract][Full Text] [Related]
18. Prospects for targeting ACKR1 in cancer and other diseases.
Crawford KS; Volkman BF
Front Immunol; 2023; 14():1111960. PubMed ID: 37006247
[TBL] [Abstract][Full Text] [Related]
19. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
[TBL] [Abstract][Full Text] [Related]
20. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia.
Olsnes AM; Hatfield KJ; Bruserud Ø
J BUON; 2009 Sep; 14 Suppl 1():S131-40. PubMed ID: 19785055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
